Overview

This trial is active, not recruiting.

Conditions neoplasms, carcinoma
Treatment ct-guided percutaneous radiofrequency ablation
Sponsor Chinese PLA General Hospital
Start date October 2015
End date October 2020
Trial size 500 participants
Trial identifier NCT02629978, CHN-PLAGH-YY-006

Summary

The objective of this study is to evaluate the outcomes of radiofrequency ablation in the treatment of patients with malignant pulmonary nodules(not exceed 3cm )who are not suitable candidates for or refuse surgical resection.

United States No locations recruiting
Other Countries No locations recruiting

Study Design

Intervention model single group assignment
Masking open label
Primary purpose treatment
Arm
(Experimental)
In this group, patients willingly receive CT-guided percutaneous radiofrequency ablation procedures are selected according to the inclusion criteria as follows. After a series of preoperative evaluation and preoperative preparation,the procedures will be performed under the CT guidance. CT/MRI scans will be ordered after 24-48 hours to see if there are complications (such as haemorrhage, pneumothorax and pleural effusion). Regularly follow-up will be carried out for several years after RFA to assess the effectiveness and safety of RFA integratedly.
ct-guided percutaneous radiofrequency ablation CT-guided percutaneous RFA
Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique will be performed in patients with malignant pulmonary nodules in this group. RFA kills the tumors by causing coagulation necrosis via tissue heating. The electrode delivers thermal energy will be inserted into the target tissues under the CT guidance to ensure the area of ablation should cover the targets and the lung tissues 0.5-1.0 cm around the tumors. Post-operative scan and laboratory test will be conducted in time.

Primary Outcomes

Measure
1- , 3- and 5-year survival rates
time frame: up to 5 years after the procedures
complication rate
time frame: During the procedure or up to 5 years after the procedures

Secondary Outcomes

Measure
changes of the size about the tumor on CT/MRI images
time frame: After the procedures up to three months

Eligibility Criteria

Male or female participants of any age.

Inclusion Criteria: 1. Histologically confirmed malignant pulmonary nodules. 2. Patients refuse or are not suitable for surgical resections. 3. 1-3 pulmonary nodules , with a maximum tumor diameter ≦30 mm. 4. Minimum distance of nodules are at least 10 mm apart from the surrounding tissues as big trachea, primary bronchi, esophagus, great vessels,heart and pleura. Exclusion Criteria: 1. Patients who has uncorrectable coagulation disorders, severe heart or pulmonary failure, or uncontrolled infections. 2. With extensive extrapulmonary or intrapulmonary metastasis. 3. Have taken anticoagulant as aspirin in one week. 4. Target nodules nearby pleura or other important hilum and mediastinum structures. 5. With metal implants are adjacent to the target tissues which will be covered with ablation area.

Additional Information

Official title Efficacy and Safety of Radiofrequency Ablation of Malignant Pulmonary Nodules
Principal investigator Yueyong Xiao
Description Percutaneous radiofrequency ablation (RFA) is a minimally invasive technique widely used to treat solid tumors. Patients with malignant pulmonary nodules will undergo a series of CT- guided percutaneous RFA procedures. During the procedures,percutaneous needles will be inserted into the target tissues under CT guidance,the needles deliver thermal energy and then destroy the tumors by causing coagulation necrosis via tissue heating. The purpose of this study is to assess the effectiveness and safety of RFA in pulmonary nodules (maximum tumor diameter ≦30 mm) was 10 mm apart from the big trachea, primary bronchi, esophagus, great vessels,heart and pleura. Preoperative and postoperative evaluations,including recent laboratory tests evaluated and imaging studies reviewed,will be performed both before and after the procedures.
Trial information was received from ClinicalTrials.gov and was last updated in December 2015.
Information provided to ClinicalTrials.gov by Chinese PLA General Hospital.